CD52 Cell Expression Evaluation, Varies
CD52 Cell Expression Evaluation, Varies-994
CD52 Cell Expression Evaluation, Varies
994
LAB994
MSO
Alemtuzumab (Campath) (CD52)
Campath-1H (CD52)
CD52
CEE52
TAE
Therapeutic Antibody Evaluation
Campath-1H (CD52)
CD52
CEE52
TAE
Therapeutic Antibody Evaluation
- Detecting cell-surface antigens on malignant cells that are potential therapeutic antibody targets, specifically CD52
- Determining the eligibility of patients for monoclonal antibody therapies
- Monitoring response to the therapeutic antibody
Whole blood or Bone Marrow
Yellow ACD (A or B)
Whole blood: 10 mL
Bone Marrow: 5 mL
Bone Marrow: 5 mL
Whole blood: 3 mL
Bone Marrow: 1 mL
Bone Marrow: 1 mL
Immediately following collection, mix sample thoroughly by gentle inverting 8 - 10 times, to prevent clotting
Send specimen in original tube. Do not aliquot.
Yellow ACD (A or B)
Whole blood: 3 mL
Bone Marrow Aspirate: 1 mL
Bone Marrow Aspirate: 1 mL
Immediately following collection, mix sample thoroughly by gentle inverting 8 - 10 times, to prevent clotting
Send specimen in original tube. Do not aliquot.
The following information is required:
- The therapeutic monoclonal antibody being used or considered
- The pertinent hematologic diseases that have been diagnosed or considered
- Specimen source
Ambient (preferred) – 4 days
Refrigerated – 4 days
Mayo Clinic Laboratories (CEE52): R-NX
Mo - Fr
1 - 4 days
Immunophenotyping
The immunophenotyping report will summarize the pattern of antigenic expression on malignant cells and, if appropriate, the normal cellular counterparts that correspond to the therapeutic monoclonal antibody target.
88184
88185 x3
88187
88185 x3
88187
03/22/2023
03/22/2023